Plain-English translation of NCT05052853 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called an NMDA enhancer can help treat people who are showing early warning signs of schizophrenia (called prodromal schizophrenia). Researchers believe this type of medication may help the brain work better in ways that could reduce these early symptoms. The study will compare the medication to a placebo (a fake pill) to see which works better.
Many people show early warning signs of schizophrenia—like unusual thoughts or difficulty concentrating—years before developing the full condition. Some lifestyle changes like exercise and education help, but they don't work for everyone. This trial is testing whether this medication could offer additional help for people whose symptoms don't improve with these basic interventions.
You likely qualify if…
You likely don't qualify if…
You would first complete a 6-week program focused on exercise and education. If your symptoms don't improve enough, you would then enter the 12-week medication trial, where you'd have a 50/50 chance of receiving the new medication or a placebo. You would visit the clinic at weeks 0, 2, 4, 6, 9, and 12 for check-ins where doctors assess your symptoms and watch for any side effects. At the beginning and end of the trial, you would also complete some thinking and memory tests.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Taiwan
Phase
Testing effectiveness
Sponsor
China Medical University Hospital
Enrollment target
~48 participants
Started
November 2021
Primary completion
October 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
13 Years – 45 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hsien-Yuan Lane, M.D., Ph.D
China Medical University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.